



Registered information

Combined General Meeting on 28 May 2010 Availability of preliminary documents

Paris (France), 7 May 2010 – The company's shareholders are invited to take part in the combined General Meeting to be held on:

28 May 2010 at 9.30 a.m

At the registered office of the Company – 65 Quai Georges Gorse
92100 Boulogne-Billancourt.

The notices of the meeting including the agenda and draft resolutions were published in the Legal Announcements newspaper « Les Petites Affiches » dated 7 May 2010 and the BALO (Bulletin des Annonces Légales Obligatoires – Bulletin of Compulsory Legal Announcements) respectively dated 21 April and 7 May 2010, and can be consulted on Ipsen's website at the following address: www.ipsen.com.

Documents required under Article R225-83 of the French Commercial Code are incorporated in Ipsen 2009 Registration Document, which is also available at the following address: www.ipsen.com. These documents are made available to shareholders from the date on which the General Meeting is convened, in accordance with current statutory provisions.

- Up to and including the fifth day before the meeting, any registered shareholder may ask the Company or the Société Générale, Département des titres, 32 rue du Champ de Tir, BP 81236 – 44312 Nantes CEDEX 3 (France) (fax: +33 (0)2 51 85 57 01) to mail him/her copies of these documents or, if need be, to e-mail them if expressly requested. Holders of bearer shares may only receive documents if they provide a certificate showing that said shares are listed on the bearer securities trading account that is held by the authorised intermediary,
- Any shareholder may consult the documents at the company's Head Office.

About Ipsen

Ipsen is a global biopharmaceutical group with total sales in excess of 1 billion euros in 2009, and total worldwide staff of more than 4,400. Its strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology, and primary care drugs, which significantly contribute to research financing. This strategy is also supported by an active policy of partnerships. Ipsen's specific Research & Development (R&D) centers and peptide & protein engineering platform give the Group a competitive edge. Almost 900 people are dedicated to the discovery and development of innovative drugs for patient care. In 2009, R&D spend reached close to €200 million, representing more than 19% of total Group sales. Ipsen's shares are traded on *Segment A* of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

For further information

Didier Véron,

Director, Public Affairs and Corporate Communications

Tél.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

e-mail: didier.veron@ipsen.com

David Schilansky

Vice President Finance

Tél.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

e-mail : david.schilansky@ipsen.com

Pierre Kemula

Investor Relations Officer

Tél.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

e-mail : pierre.kemula@ipsen.com